SCYNEXIS (SCYX): Prakiraan wutah bathi kanggo taun ngarep

The consensus for next year's earnings per share reflects the results of experienced management's efforts to optimize R&D and liquidity for SCYNEXIS, Inc. (SCYX). Stable FCF is driven by royalties from global partners, while business resilience is based on the critical necessity of antifungal therapy regardless of economic conditions. The current level describes the value of 5.20, capturing analysts' yield expectations for SCYNEXIS, Inc. (SCYX).

SCYX - Proyeksi tambahing bathi saben saham ing taun ngarep SCYNEXIS Inc ing rentang 04.07.2022 - 10.11.2026

Rincian metrik lan analitis perusahaan SCYNEXIS (SCYX)

- rega saham lan konsensus proyeksi valuasi:

Rega saham SCYNEXIS Inc|SCYX - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Kapitalisasi pasar SCYNEXIS|SCYX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- indikator kapitalisasi buku:

Nilai Akuntansi saben Saham SCYNEXIS|SCYX - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku scynexis.com|SCYX - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

- statistik bathi lan rasio pasar:

SCYX - Penghasilan resik|Bathi mangsa ngarep SCYNEXIS, Inc.|SCYX - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep SCYNEXIS Inc|SCYX - Rasio P/E diaturake wutah|Pangali EV/EBITDA SCYNEXIS|SCYX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan SCYNEXIS|SCYX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan scynexis.com|SCYX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep SCYNEXIS, Inc.

Analisis umum perusahaan:SCYX, SCYNEXIS, Inc.

This indicator assesses the expected earnings per share (EPS) dynamics, reflecting the analysts' consensus forecast on business efficiency adjusted for cost inflation. For SCYNEXIS (SCYX), the analyst EPS growth chart demonstrates the commercialization potential of Brexafemme and the success of new clinical phases amid strict FDA oversight. The metric's positive trend confirms the scalability of the ecosystem, enhancing the asset's fundamental investment attractiveness.

Analisis pesaing